抗病毒治疗降低非肝硬化慢性乙型肝炎患者的肝硬化风险:四城市安全网医疗系统研究
该回顾性队列研究纳入2010至2018年4个美国城市安全网医疗系统的4064例非肝硬化、无HIV的慢性乙型肝炎成人患者,其中23.2%接受抗病毒治疗。倾向性评分匹配后(各428例),治疗与肝硬化风险降低(HR 0.65,95%CI 0.46-0.92,P=0.015)及肝硬化、肝细胞癌或死亡复合终点风险降低(HR 0.67,95%CI 0.49-0.94,P=0.023)相关。女性、年龄<45岁和亚裔患者从抗病毒治疗中获益更明显。
要点
- 抗病毒治疗可显著降低非肝硬化CHB患者肝硬化风险(HR 0.65)。
- 治疗亦降低肝硬化、HCC或死亡复合终点风险(HR 0.67)。
- 女性、<45岁及亚裔患者从治疗中获益更显著。
核心结论
- 在倾向性评分匹配的非肝硬化CHB队列中,抗病毒治疗与肝硬化风险及肝硬化、HCC或死亡复合终点风险显著降低相关。
研究设计与样本
- 回顾性队列研究,纳入2010至2018年4个美国城市安全网医疗系统的非肝硬化、无HIV的CHB成人患者。
- 共纳入4064例CHB患者,其中23.2%接受抗病毒治疗,76.8%未治疗;倾向性评分匹配后各428例。
- 采用Kaplan-Meier方法和校正Cox比例风险模型评估治疗对肝硬化、HCC、死亡及复合终点的影响。
主要发现
- 匹配队列中,抗病毒治疗与较低的肝硬化风险相关(HR 0.65,95%CI 0.46-0.92,P=0.015)。
- 抗病毒治疗与较低的肝硬化、HCC或死亡复合终点风险相关(HR 0.67,95%CI 0.49-0.94,P=0.023)。
- 女性相比男性、非洲裔美国人相比非西班牙裔白人,肝硬化风险显著更低。
- 按年龄、性别和种族分层后,抗病毒治疗降低肝硬化风险的获益主要见于女性、年龄<45岁和亚裔CHB患者。
临床怎么用
- 对非肝硬化CHB患者,尤其是女性、年龄<45岁和亚裔人群,应积极评估并启动抗病毒治疗以降低肝硬化风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To evaluate the impact of chronic hepatitis B virus infection (CHB) treatment on risk of cirrhosis, liver-related outcomes, and death among a diverse CHB cohort with a large proportion of African Americans. METHODS: Adults with noncirrhotic CHB without human immunodeficiency virus from 2010 to 2018 were retrospectively evaluated across 4 US safety-net health systems. CHB was identified with International Classification of Diseases, Ninth Revision/Tenth Revision diagnosis coding and confirmatory laboratory data. Propensity-score matching, Kaplan-Meier methods, and adjusted Cox proportional hazards models were used to evaluate impact of CHB treatment on risk of cirrhosis, hepatocellular carcinoma (HCC), death, and composite of cirrhosis, HCC, or death. RESULTS: Among 4,064 CHB patients (51.9% female, 42.0% age <45 years, 31.6% African American, 26.6% Asian, 26.7% Hispanic), 23.2% received CHB antiviral therapy and 76.8% did not. Among the propensity score-matched cohort (428 treated and 428 untreated), CHB treatment was associated with lower risk of cirrhosis (hazards ratio 0.65, 95% confidence interval 0.46-0.92, P = 0.015) and composite of cirrhosis, HCC, or death (hazards ratio 0.67, 95% confidence interval 0.49-0.94, P = 0.023). Females vs males and African Americans vs non-Hispanic whites had significantly lower risk of cirrhosis. When treatment effects were stratified by age, sex, and ethnicity, the benefits of antiviral therapies in reducing risk of cirrhosis were seen primarily in CHB patients who were females, age <45 years, and of Asian ethnicity. DISCUSSION: Our propensity score-matched cohort of noncirrhotic CHB patients demonstrated significant reductions in risk of cirrhosis due to CHB treatment.
引用
- Wong RJ, Jain MK, Therapondos G, et al. Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems. Am J Gastroenterol. 2021. PMID: 33661148. doi:10.14309/ajg.0000000000001195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。